Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study - 28/02/23
, Masatoshi Eto, ProfMD b, Robert Motzer, ProfMD c, Ugo De Giorgi, MD d, Tomas Buchler, ProfMD e, Naveen S Basappa, MD f, María José Méndez-Vidal, MD g, Sergei Tjulandin, ProfMD h, Se Hoon Park, ProfMD i, Bohuslav Melichar, ProfMD j, Thomas Hutson, ProfDO k, Carlos Alemany, MD l, Bradley McGregor, MD a, Thomas Powles, ProfMD m, n, Viktor Grünwald, ProfMD o, Boris Alekseev, ProfMD p, Sun Young Rha, ProfMD q, Evgeny Kopyltsov, MD r, Anil Kapoor, ProfMD s, Teresa Alonso Gordoa, MD t, Jeffrey C Goh, MD u, v, Michael Staehler, ProfMD w, Jaime R Merchan, ProfMD x, Ran Xie, PhD y, Rodolfo F Perini, MD aa, Kalgi Mody, MD z, Jodi McKenzie, PhD z, Camillo G Porta, ProfMD abSummary |
Background |
In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus sunitinib in patients with advanced renal cell carcinoma (data cutoff Aug 28, 2020). We aimed to assess overall survival based on 7 months of additional follow-up.
Methods |
This is a protocol-prespecified updated overall survival analysis (data cutoff March 31, 2021) of the open-label, phase 3, randomised CLEAR trial. Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy for renal cell carcinoma, including anti-vascular endothelial growth factor therapy, or any systemic investigational anticancer drug, were eligible for inclusion from 200 sites (hospitals and cancer centres) across 20 countries. Patients were randomly assigned (1:1:1) to receive lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days; lenvatinib plus pembrolizumab group), lenvatinib (18 mg per day orally) plus everolimus (5 mg per day orally; lenvatinib plus everolimus group [not reported in this updated analysis]) in 21-day cycles, or sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off; sunitinib group). Eligible patients were at least 18 years old with a Karnofsky performance status of 70 or higher. A computer-generated randomisation scheme was used, and stratification factors were geographical region and Memorial Sloan Kettering Cancer Center prognostic groups. The primary endpoint was progression-free survival assessed by independent imaging review according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). In this Article, extended follow-up analyses for progression-free survival and protocol-specified updated overall survival data are reported for the intention-to-treat population. No safety analyses were done at this follow-up. This study is closed to new participants and is registered with ClinicalTrials.gov, NCT02811861.
Findings |
Between Oct 13, 2016, and July 24, 2019, 1417 patients were screened for inclusion in the CLEAR trial, of whom 1069 (75%; 273 [26%] female, 796 [74%] male; median age 62 years [IQR 55–69]) were randomly assigned: 355 (33%) patients (255 [72%] male and 100 [28%] female) to the lenvatinib plus pembrolizumab group, 357 (33%) patients (275 [77%] male and 82 [23%] female) to the sunitinib group, and 357 (33%) patients to the lenvatinib plus everolimus group (not reported in this updated analysis). Median follow-up for progression-free survival was 27·8 months (IQR 20·3–33·8) in the lenvatinib plus pembrolizumab group and 19·4 months (5·5–32·5) in the sunitinib group. Median progression-free survival was 23·3 months (95% CI 20·8–27·7) in the lenvatinib plus pembrolizumab group and 9·2 months (6·0–11·0) in the sunitinib group (stratified hazard ratio [HR] 0·42 [95% CI 0·34–0·52]). Median overall survival follow-up was 33·7 months (IQR 27·4–36·9) in the lenvatinib plus pembrolizumab group and 33·4 months (26·7–36·8) in the sunitinib group. Overall survival was improved with lenvatinib plus pembrolizumab (median not reached [95% CI 41·5–not estimable]) versus sunitinib (median not reached [38·4–not estimable]; HR 0·72 [95% CI 0·55–0·93]).
Interpretation |
Efficacy benefits of lenvatinib plus pembrolizumab over sunitinib were durable and clinically meaningful with extended follow-up. These results support the use of lenvatinib plus pembrolizumab as a first-line therapy for patients with advanced renal cell carcinoma.
Funding |
Eisai and Merck Sharp & Dohme.
Le texte complet de cet article est disponible en PDF.Plan
Vol 24 - N° 3
P. 228-238 - mars 2023 Retour au numéro
Article précédent
- Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
- Janet E Brown, Kara-Louise Royle, Walter Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, Rhona McMenemin, Poulam Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter Selby, Fiona Collinson, STAR Investigators, Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, Marios Decatris, Carys Thomas, Joanna Gale, James McAleer, Alison Clayton, Ekaterini Boleti, Thomas Geldart, Santhanam Sundar, Jason Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, Rajaguru Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, Nicholas Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, Sharon Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela Scott, Mark Baxter, Anna Mullard, Pasquale Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry Taylor, Christos Mikropoulos, Martin Highley, Dakshinamoorthy Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, Urmila Barthakur, Erica Beaumont, Caroline Manetta, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti
- Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis
- Hisham Mehanna, Miren Taberna, Christian von Buchwald, Sara Tous, Jill Brooks, Marisa Mena, Francisca Morey, Christian Grønhøj, Jacob Høygaard Rasmussen, Martin Garset-Zamani, Laia Bruni, Nikolaos Batis, Ruud H Brakenhoff, C René Leemans, Robert J Baatenburg de Jong, Jens Peter Klussmann, Nora Wuerdemann, Steffen Wagner, Tina Dalianis, Linda Marklund, Haïtham Mirghani, Andrew Schache, Jaqueline A James, Shao Hui Huang, Brian O’Sullivan, Paul Nankivell, Martina A Broglie, Markus Hoffmann, Elgar Susanne Quabius, Laia Alemany, HNCIG-EPIC group, Hisham Mehanna, Miren Taberna, Christian von Buchwald, Sara Tous, Shao Hui Huang, Brian O’Sullivan, Martin Garset-Zamani, Jill Brooks, Nikolaos Batis, Tessa Fulton-Lieuw, Paul Nankivell, Andrew Schache, Jacqueline A James, Ruud H Brakenhoff, C Rene Leemans, Danielle AM Heideman, Elisabeth Bloemena, Irene Nauta, Robert Baatenburg de Jong, Tina Dalianis, Linda Marklund, Haïtham Mirghani, Steffen Wagner, Claus Wittekindt, Jens Peter Klussmann, Nora Wuerdemann, Alexander Quaas, Shachi Jenny Sharma, Margaret Maltseva, Philipp Zimmermann, Markus Hoffmann, Elgar Susanne Quabius, Martina Broglie Däppen, Leitende Ärztin, Laia Bruni, Marisa Mena, Francisca Morey, Laia Alemany
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?